How do patients with NSCLC & very high PD-L1 levels ≥90% do with 1st-line pembrolizumab? Multi-institutional collaboration led by outstanding Elizabeth Jimenez Aguilar & Biagio Ricciuti now online @Annals_Oncology @BiagioMD @Elizabethjimag @DanaFarber Tweet added by Mark Awad @DrMarkAwad | Pikagi

Pikagi

@DrMarkAwad

Mark Awad

5 years

How do patients with NSCLC & very high PD-L1 levels ≥90% do with 1st-line pembrolizumab? Multi-institutional collaboration led by outstanding Elizabeth Jimenez Aguilar & Biagio Ricciuti now online @Annals_Oncology @BiagioMD @Elizabethjimag @DanaFarber

Tweet media one

Tweet media two

2

50

103

Replies

@NicoleKuderer

Nicole Kuderer, MD, MS, FASCO 🌎🇺🇸🇪🇺🇺🇦🌏

5 years

@DrMarkAwad @DrChoueiri @Annals_Oncology @BiagioMd @Elizabethjimag @DanaFarber 👉Congrats. Very imporant info! For longitudinal variable a single cutpoint is somewhat arbitrary & loses lots of info. Quartiles or at least tertiles are more clinically valid & avoids missing large % of pts also likely to have a high response rate. #IO #biomarkers PD-L1

0

2

3